TNF and neoplasm: In melanoma models, immunotherapies combining tumour necrosis factor (TNF), anti-CD40 and anti-tumour-associated antigen antibody have also been shown to polarise neutrophils to an anti-tumour phenotype promoting tumour clearance via ROS secretion and improved antibody-dependant cellular cytotoxicity (ADCC).